GlassScriptPhysician profile
Christopher Michael Bair
NPI 1245763390
$8,932.25
in general payments reported to CMS, 2019-2025
16 companies · $1,103 in 2025
The $1,103 reported for 2025 was more than what 75% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $28.97 · 2021: $337 · 2022: $35.01 · 2023: $6,233 · 2024: $992 · 2025: $1,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,935 · Food and Beverage: $2,881 · Travel and Lodging: $512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,935.00 |
| Food and Beverage | $2,880.93 |
| Travel and Lodging | $511.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $5,838.20 | 2023-2025 | Vabysmo, Susvimo |
| Regeneron Healthcare Solutions, INC. | $713.15 | 2019-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $641.66 | 2023-2025 | Syfovre |
| Astellas Pharma US INC | $376.25 | 2023-2025 | Izervay |
| Abbvie INC. | $274.96 | 2024-2025 | |
| Alcon Vision LLC | $250.98 | 2019-2025 | Clareon |
| Alimera Sciences, INC. | $209.23 | 2023-2024 | Iluvien, Yutiq |
| Oculus Surgical INC. | $161.56 | 2021 | |
| Sight Sciences, INC. | $105.17 | 2025 | Omni Surgical System |
| Harrow Eye, LLC | $103.53 | 2024-2025 | Iheezo, Triesence |
| Ani Pharmaceuticals, INC. | $75.72 | 2025 | Yutiq, Iluvien |
| Ocular Therapeutix, INC. | $53.32 | 2023-2024 | Dextenza |
| Allergan, INC. | $46.58 | 2021 | |
| Eyepoint US, INC. | $35.01 | 2022 | |
| Glaukos Corporation | $28.97 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $17.96 | 2025 | Xipere |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.